These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 16573787)

  • 1. Systematic review: the use of mesalazine in inflammatory bowel disease.
    Bergman R; Parkes M
    Aliment Pharmacol Ther; 2006 Apr; 23(7):841-55. PubMed ID: 16573787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
    Prakash A; Markham A
    Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A practical guide to the management of distal ulcerative colitis.
    Ardizzone S; Bianchi Porro G
    Drugs; 1998 Apr; 55(4):519-42. PubMed ID: 9561342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
    Schroeder KW
    Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
    Nguyen NH; Fumery M; Dulai PS; Prokop LJ; Sandborn WJ; Murad MH; Singh S
    Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):742-753. PubMed ID: 30122356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
    Hanauer SB
    Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():37-40. PubMed ID: 16961743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.
    Vecchi M; Meucci G; Gionchetti P; Beltrami M; Di Maurizio P; Beretta L; Ganio E; Usai P; Campieri M; Fornaciari G; de Franchis R
    Aliment Pharmacol Ther; 2001 Feb; 15(2):251-6. PubMed ID: 11148445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease.
    Thomson AB
    Aliment Pharmacol Ther; 1991 Oct; 5(5):449-70. PubMed ID: 1793778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesalazine for the treatment of inflammatory bowel disease.
    Criscuoli V; Modesto I; Orlando A; Cottone M
    Expert Opin Pharmacother; 2013 Aug; 14(12):1669-78. PubMed ID: 23767798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is maintenance therapy always necessary for patients with ulcerative colitis in remission?
    Ardizzone S; Petrillo M; Imbesi V; Cerutti R; Bollani S; Bianchi Porro G
    Aliment Pharmacol Ther; 1999 Mar; 13(3):373-9. PubMed ID: 10102971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.
    Safdi AV; Cohen RD
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1179-86. PubMed ID: 17944732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
    Mulder CJ; van den Hazel SJ
    Mediators Inflamm; 1998; 7(3):135-6. PubMed ID: 9705596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesalazine in childhood inflammatory bowel disease.
    Barden L; Lipson A; Pert P; Walker-Smith JA
    Aliment Pharmacol Ther; 1989 Dec; 3(6):597-603. PubMed ID: 2577501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rescue therapy with sulfasalazine prior to immunosuppressive or biological agents in ulcerative colitis poorly controlled with mesalazine].
    Martínez González J; Busto Bea V; Mesonero Gismero F; Parejo Carbonell S; Garrido E; López San Román A
    Gastroenterol Hepatol; 2013 Jan; 36(1):7-10. PubMed ID: 23195755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.
    Harris MS; Lichtenstein GR
    Aliment Pharmacol Ther; 2011 May; 33(9):996-1009. PubMed ID: 21385194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
    Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis.
    Barberio B; Segal JP; Quraishi MN; Black CJ; Savarino EV; Ford AC
    J Crohns Colitis; 2021 Jul; 15(7):1184-1196. PubMed ID: 33433562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.